Preferential expression of mutant ABCD1 allele is common in adrenoleukodystrophy female carriers but unrelated to clinical symptoms by E. Salsano et al.
RESEARCH Open Access
Preferential expression of mutant ABCD1 allele is
common in adrenoleukodystrophy female carriers
but unrelated to clinical symptoms
Ettore Salsano1†, Silvia Tabano2,3†, Silvia M Sirchia2,3, Patrizia Colapietro2,3, Barbara Castellotti4, Cinzia Gellera4,
Marco Rimoldi4, Viviana Pensato4, Caterina Mariotti4, Davide Pareyson1, Monica Miozzo2,3* and Graziella Uziel5
Abstract
Background: Approximately 20% of adrenoleukodystrophy (X-ALD) female carriers may develop clinical
manifestations, typically consisting of progressive spastic gait, sensory deficits and bladder dysfunctions. A skewing
in X Chromosome Inactivation (XCI), leading to the preferential expression of the X chromosome carrying the
mutant ABCD1 allele, has been proposed as a mechanism influencing X-linked adrenoleukodystrophy (X-ALD)
carrier phenotype, but reported data so far are conflicting.
Methods: To shed light into this topic we assessed the XCI pattern in peripheral blood mononuclear cells (PBMCs)
of 30 X-ALD carriers. Since a frequent problem with XCI studies is the underestimation of skewing due to an
incomplete sample digestion by restriction enzymes, leading to variable results, we developed a pyrosequencing
assay to identify samples completely digested, on which to perform the XCI assay. Pyrosequencing was also used
to quantify ABCD1 allele-specific expression. Moreover, very long-chain fatty acid (VLCFA) levels were determined in
the same patients.
Results: We found severely (≥90:10) or moderately (≥75:25) skewed XCI in 23 out of 30 (77%) X-ALD carriers and
proved that preferential XCI is mainly associated with the preferential expression of the mutant ABCD1 allele,
irrespective of the manifestation of symptoms. The expression of mutant ABCD1 allele also correlates with plasma
VLCFA concentrations.
Conclusions: Our results indicate that preferential XCI leads to the favored expression of the mutant ABCD1 allele.
This emerges as a general phenomenon in X-ALD carriers not related to the presence of symptoms. Our data
support the postulated growth advantage of cells with the preferential expression of the mutant ABCD1 allele, but
argue against the use of XCI pattern, ABCD1 allele-specific expression pattern and VLCFA plasma concentration as
biomarkers to predict the development of symptoms in X-ALD carriers.
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Background
X-linked adrenoleukodystrophy (X-ALD,
OMIM#300100) encompasses a spectrum of X-linked
metabolic diseases due to mutations in the ABCD1
(ATP-Binding Cassette, Subfamily D, Member 1) gene
mapping to Xq28. ABCD1 encodes for an integral
peroxisomal membrane protein which is hypothesized to
be necessary for transferring very long-chain fatty acids
(VLCFAs) or their activated metabolites into the peroxi-
somes, where they are degraded through the beta-oxida-
tion pathway. Hence, X-ALD is biochemically
characterized by excessive plasma and tissue accumula-
tion of VLCFAs. It has been suggested that the conse-
quence of the impairment of VLCFA beta-oxidation is
an oxidative stress, provoking an axonal damage [1].
Although X-ALD is associated with mutations in the
sole ABCD1 gene, several different phenotypes are
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recognized, mainly depending on age of onset, and pre-
sence and type of neurological findings. This heteroge-
neous spectrum comprises the development of
symptoms in about 20% of female carriers, usually in
their thirties [2,3]. Symptoms of female X-ALD carriers
typically consist of an AMN-like phenotype (i.e. progres-
sive spastic gait, sensory deficits and bladder dysfunc-
tion, but no adrenal insufficiency).
X Chromosome Inactivation (XCI) is the silencing of
one of the two X chromosomes in mammal female cells,
to ensure an equal expression of X-linked genes
between the two sexes. This process takes place during
early development, when, within the same nucleus, one
X is transcriptionally silenced while the other remains
active. Usually, the choice of which X to inactivate is
random, therefore about 50% of cells express genes
from the paternal-derived X chromosome, and 50%
from the maternal one. Once established, the inactive
state is stably maintained through cell division so that
females can be considered as a “mosaic” in regards to X
chromosome gene expression. Importantly, not all X-
linked genes are completely silenced on the inactive X,
and some of them escape inactivation, being expressed
by both the active and the inactive X.
In X-linked disorders, the widely variable penetrance
in female carriers can be dependent upon multiple
mechanisms and can be related to the XCI pattern [4].
In a subgroup of females, XCI is preferential and results
in an unbalanced expression of X-linked genes among
the cells, usually favoring the expression of the wild-
type allele [5,6]. The preferential expression of the
mutant allele is also conceivable and could be related to
the presence of symptoms.
In X-ALD female carriers, the hypothesis that the
skewing of XCI, favoring the expression of the mutant
ABCD1 allele in peripheral blood mononuclear cells
(PMBCs), may be related to clinical symptoms is intri-
guing. However, conflicting results have been reported
by different authors: Watkiss et al. [7] failed to find any
association in 12 X-ALD female carriers, whereas Maier
et al. [8], who analyzed 22 X-ALD female carriers,
found that skewed XCI was related to neurological man-
ifestation. Moreover, the question of whether the wild-
type or the mutant allele is predominantly active in
symptomatic female carriers remains mostly unan-
swered, since Maier et al. found inconsistent results in
the fibroblasts of only three carriers [8].
Certainly, the demonstration of an unambiguous rela-
tion between skewed XCI in PBMCs and clinical symp-
toms would have important consequences on the
clinical practice. Indeed, it would be a valuable para-
meter to early identify the subgroup of X-ALD female
carriers with a higher-risk of becoming symptomatic
and for whom a possible preventive therapy would be
warranted [9]. With the aim of shedding light on this
topic, we assessed the XCI pattern in 30 X-ALD female
carriers and evaluated its relation with clinical findings.
In addition, we quantitatively measured the ABCD1
allele-specific expression in our cohort of carriers, in
order to establish whether the direction of XCI pattern
favors the expression of the mutant or the wild-type
allele. Finally, we investigated the correlations between
VLCFA levels and the degree of expression of mutant
ABCD1 allele in PBMCs.
Patients and methods
Patients
We studied 31 women from 14 families segregating
ABCD1 mutations (Table 1). See Additional file 1, Fig-
ure S1 and Table 2 for further information.
Mutational Analysis and Biochemical Evaluation
After the informed consent was obtained, the genomic
DNA of each female was extracted from blood samples
collected in potassium EDTA tubes using standard pro-
cedures. The coding sequences (exons 1-10) and intron-
exon boundaries of the ABCD1 gene were analyzed for
mutations by direct sequence analysis using an auto-
mated system (ABI 3130xl). The primers used are avail-
able on request. The missense unknown variants were
tested in 100 healthy Italian donors by direct sequen-
cing. Major deletions in the ABCD1 gene were detected
using the SALSA MLPA kit P049 SLC6A8 - ABCD1
(MRC-Holland). Note that deletions of probe recogni-
tion sequences in males are apparently due to the
absence of the probe amplification product, whereas in
heterozygous females, we detect a 35-50% reduction in
the relative peak area of the amplification product of
that probe. However, mutations and/or polymorphisms
very close to the probe ligation site may also result in a
reduced relative peak area. Therefore, apparent deletions
detected by a single probe require confirmation by other
methods (i.e., Real Time PCR, High Resolution Melting
assay, or both). VLCFAs were quantified in plasma by
standard procedures [10-12]
X-Chromosome Inactivation (XCI) Assay and
Pyrosequencing™ technology
The XCI pattern was assessed in DNA from white blood
cells (WBCs) of 30 X-ALD carriers and 268 age-
matched controls using methylation sensitive restriction
enzymes, flanked by HUMARA (Androgen Receptor
locus) and DXS6673E Single Tandem Repeats (STRs).
PCR was performed on samples before and after enzy-
matic digestions, using the HpaII and HhaI enzymes
(Boehringer Ingelheim, Mannheim, Germany) for
HUMARA and HhaI and RsaI for DXS6673E as pre-
viously reported [13,14]. All samples were tested in
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Table 1 Clinical Findings, Genotype, X-Chromosome Inactivation (XCI), ABCD1 Allele-Specific Expression (ASE) and
Biochemical Findings (VLCFA plasma levels) of X-ALD carriers
Nr of family,
consultants
Age
(yrs)
Presence of symptoms (age
at onset, yrs)
Mutations XCI
pattern
ABCD1 ASE
(mut:wt)
C26
(nv)
C26/C22
(nv)
C24/C22
(nv)
F1 II-3 67 Yes (45) 410G > A W137X 97:03 84:16 1,09
(<0,75)
48 (<17) 1644
(<1100)
F1 III-2 34 No 410G > A W137X 91:09 nd 0,58
(<0,75)
47 (<17) 1482
(<1100)
F2 I-2 61 Yes (59) 427C > G P143A 71:29 93:07 0,85
(<0,75)
18 (<17) 1222
(<1100)
F2 II-1 38 No 427C > G P143A 85:15 83:17 nd nd nd
F2 II-2 35 No 427C > G P143A 76:24 77:23 nd nd nd
F3 II-2 73 Yes (45) 428C > A P143H 60:40 38:62 1,45
(<1,50)
28 (<40) 700
(<820)
F3 III.1 46 No 428C > A P143H 84:16 84:16 1,53
(<1,50)
40 (<40) 860
(<820)
F3 III-2 50 No 428C > A P143H 83:17 75:25 1,75
(<1,50)
37 (<40) 733
(<820)
F4 II-3 75 Yes (50) 652C > T;
664G > T
P218S;
V222L
81:19 82:18 1,57
(<0,75)
19 (<17) 1680
(<1100)
F4 III-1 44 No 652C > T;
664G > T
P218S;
V222L
83:17 81:19 2,38
(<1,50)
53 (<40) 1424
(<820)
F4 III-3 45 Yes (29) 652C > T;
664G > T
P218S;
V222L
89:11 82:18 1,00
(<0,75)
36 (<17) 1611
(<1100)
F5 II-1 55 Yes (54) 1202G > A R401Q 98:02 82:18 1,96
(<1,50)
38 (<40) 1031
(<820)
F6 II-1 76 Yes (58) 1727T > C L576P 73:27 76:24 2,10
(<0,75)
21 (<17) 1039
(<1100)
F7 I-2 72 No 1772G > A R591Q n/a n/a 1,23
(<1,5)
16 (<40) 798
(<820)
F7 II-1 44 Yes (34) 1772G > A R591Q 96:04 97:03 2,7
(<1,50)
56 (<40) 957
(<820)
F8 II-1 62 Yes (40) 1992G > A W664X 83:17 82:18 3,08
(<1,50)
56 (<40) 1132
(<820)
F9 II-1 63 No 293C > T S98L 83:17 93:07 1,82
(<1,50)
37 (<40) 888
(<820)
F9 II-3 57 No 293C > T S98L 79:21 75:25 1,99
(<1,50)
42 (<40) 913
(<820)
F9 III-2 20 No 293C > T S98L 75:25 61:39 2,65
(<1,50)
46 (<40) 1149
(<820)
F10 I-2 63 No 443A > G N148S 86:14 42:58 2,16
(<1,50)
42 (<40) 788
(<820)
F10 II-2 40 No 443A > G N148S 96:04 84:16 2,17
(<1,50)
43 (<40) 757
(<820)
F11 III-1 67 No 1165C > T R389C 52:48 72:28 0,7
(<1,50)
13 (<40) 572
(<820)
F11 III-3 64 No 1165C > T R389C 78:22 34:66 1,1
(<1,50)
16 (<40) 823
(<820)
F11 III-5 49 No 1165C > T R389C 98:02 20:80 1,05
(<1,50)
16 (<40) 848
(<820)
F11 III-6 46 No 1165C > T R389C 71:29 74:26 1,30
(<1,50)
18 (<40) 1000
(<820)
F11 V-1 26 No 1165C > T R389C 57:43 58:42 0,68
(<1,50)
14 (<40) 663
(<820)
F12 I-2 53 No 1211C > A S404X 95:05 09:91 nd nd nd
F13 I-2 60 No del. ex8-10 n/a 76:24 nd nd nd nd
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duplicate and one male DNA sample was included in
each experiment as a control for enzymatic digestion.
PCR products were run by capillary electrophoresis and
XCI values were determined in heterozygous cases using
the formula previously reported [15]. The XCI pattern
was defined as “moderately” skewed in the presence of
an XCI ratio ≥75:25 and “severely” skewed when the
XCI ratio was ≥90:10, similar to previous reports [15].
Our prior experience suggests that the skewing of XCI
can be underestimated, as the cleavage of the
Table 2 Clinical findings of the symptomatic ALD female carriers
F1 II-3 F2 I-2 F3 II-2 F4 II-3 F4 III-3 F5 II-1 F6 II-1 F7 II-1 F8 II-1
Age at
evaluation
(yrs)
67 61 73 75 45 55 76 44 62
Age at
onset
45 59 45 50 29 54 58 34 40
Symptoms
at onset
Difficulty to
walk
Difficulty to
walk and
imbalance
Difficulty to
walk
Difficulty to
walk
Difficulty to
walk & Back
pain
Mild leg
stiffness
Difficulty to
walk
Difficulty to
run
Difficulty to
walk & Leg
stiffness
Gait at
examination
Paraparetic
& ataxic gait
Paraparetic Paraparetic Paraparetic Paraparetic Near-normal Paraparetic Paraparetic Paraparetic
Ambulation
Index1
4 3 6 8 5 1 4 4 4
Muscle tone
(legs)2
Increased (+
+)
Increased (+) Increased (+
++)
Increased (+
+)
Increased (+) Increased (+) Increased
(+)
Increased (+
+)
Increased (+
+)
Tendon
reflexes
Increased Increased Increased Increased Increased Increased Increased Increased Increased
Plantar
response
Extensor Extensor Extensor Extensor Extensor Extensor Bilaterally
indifferent
Extensor Extensor
Vibration
sense (legs)
3
Impaired (+
+)
Impaired (++) Impaired (+
+)
Impaired (+
+)
Impaired (+) Impaired (+
+)
Impaired (+) Impaired (+
+)
Impaired (++)
Bladder
function
Urge-
incontinence
Urge-
incontinence
Urge-
incontinence
Urge-
incontinence
Urge-
incontinence
Normal Incontinence Normal Normal
Other signs No Lumbar
hyperlordosis
Mild upper
limb ataxia
No No Lumbar
hyperlordosis
No Lumbar
hyperlordosis
Lumbar
hyperlordosis
Brain MRI Normal Normal Normal n.d. Normal Normal Cerebral
atrophy
Normal Normal
MEPs n.d. Abnormal Abnormal n.d. n.d. Near-normal Abnormal Abnormal Abnormal
SSEPs n.d. Abnormal Abnormal n.d. n.d. Abnormal Abnormal Abnormal n.d.
VEPs n.d. Abnormal Normal n.d. n.d. Abnormal n.d. Normal n.d.
BAEPs n.d. Abnormal Abnormal n.d. n.d. Normal n.d. Abnormal n.d.
NCVs n.d. Normal Normal n.d. Abnormal Normal Abnormal Abnormal Normal
Serum
Cortisol
Normal n.d. Normal n.d. n.d. Normal n.d. Normal n.d.
BAEPs, brainstem auditory evoked potentials, MEPs, motor evoked potentials; MRI, magnetic resonance imaging; n.d. = not done; NCVs, nerve conduction
velocities; SSEPs, somato-sensory evoked potentials; VEPs, visual evoked potentials.
1For details, see Hauser et al., 1983 [23].
2 + = mild; ++ = moderate; +++ = severe.
3 + = vibration sense decreased in feet; ++ = vibration sense absent in feet, and lowered in lower legs [24].
Table 1 Clinical Findings, Genotype, X-Chromosome Inactivation (XCI), ABCD1 Allele-Specific Expression (ASE) and Bio-
chemical Findings (VLCFA plasma levels) of X-ALD carriers (Continued)
F13 II-2 37 No del. ex8-10 n/a 93:07 nd 1,99
(<1,50)
37 (<40) 1040
(<820)
F13 II-3 30 No del. ex8-10 n/a 99:01 nd nd nd nd
F14 I-2 52 No del. ex7-10 n/a 69:31 nd 1,91
(<1,50)
34 (<40) 606
(<820)
del, deletion; n/a, not applicable; nv, normal value; nd, not done.
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unmethylated restriction sites can be incomplete due to
partial efficiency of methyl-sensitive restriction enzymes.
This phenomenon is “sample-dependent” (i.e. a single
sample could be incompletely digested, even if the con-
trol male is fully digested), and may explain the high
variability observed among different studies about the
XCI pattern. To prevent this bias, we tested different
restriction enzymes, and we used Pyrosequencing™
technology to detect the efficiency of the digestion
(Additional file 2, Figure S2). Pyrosequencing allowed us
to quantitatively evaluate the percentage of C/T (corre-
sponding to methylated/unmethylated allele) in a sam-
ple. The digestion was considered complete when the
percentage of residual unmethylated allele was below
5%. This procedure was performed in all samples and
XCI assay was assessed only in samples showing a com-
plete digestion.
RNA extraction and Allele-Specific Expression (ASE) Assay
The RNAs were collected using Tempus Blood RNA
tubes (Applied Biosystems) and isolated using the Tem-
pus Spin RNA Isolation kit (Applied Biosystems),
according to the manufacturer’s procedures. cDNAs
were synthesized using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems).
To assess the allele-specific expression (ASE), ABCD1
cDNA fragments containing the mutation were ampli-
fied, and PCR products were sequenced by the Pyro-
Mark ID instrument (Qiagen) following the
manufacturer’s instructions, and using specific PCR and
sequencing primers (Additional file 3, Table S1). The
contribution of the mutant and wild-type alleles were
quantitatively measured by the Pyro Mark ID software
v1.0.9 (Qiagen, Chatsworth, CA), which gives the per-
centage ratio of each allele. The quantification is highly
precise with an error estimated as ≤10%. For this reason,
we considered that one allele was higher expressed than
the other, when their ratio was equal or higher than 1.5
(60:40). For each sample, allele-specific expression value
represents the mean of at least two independent PCR
and pyrosequencing experiments.
Statistical Analyses
Fisher’s exact test, Mann-Whitney Test and Spearman
correlation were performed using GraphPad Prism ver-
sion 5.04 for Windows, GraphPad Software, San Diego
California USA.
Results
Clinical findings
We investigated 22 asymptomatic and 9 symptomatic
ALD female carriers whose clinical, genetic and bio-
chemical findings are summarized in Table 1. The clini-
cal features of symptomatic women were similar to
those previously reported, mainly characterized by spas-
tic paraplegia, lower limb sensory disturbances, and neu-
rogenic bladder (Table 2) [3,9]. The age at evaluation
was significantly higher in the symptomatic than in
asymptomatic females (62.0 ± 12.1 vs. 47.5 ± 14.1years;
p = 0.0199, Mann-Whitney test). However, we did not
find any significant difference between the age at onset
of clinical symptoms in symptomatic carriers and the
age at evaluation in the asymptomatic ones (46.0 ± 10.4
vs. 47.5 ± 14.1 years; p = 0.7276, Mann-Whitney test).
Mutational analysis
The ABCD1 mutations of the female carriers are sum-
marized in Table 1. We found 15 different ABCD1
mutations, five of which were new, according to the X-
linked Adrenoleukodystrophy Database (http://www.x-
ald.nl/). Additional information about the position on
ABCD1 gene are available in Additional file 4, Table S2.
As one carrier (F7 I-2) was a mosaic for the c.1772G >
A mutation, she was excluded from the statistical
analyses.
X Chromosome Inactivation pattern
XCI analysis was performed in 30 X-ALD carriers and in
268 age-matched healthy females. As shown in Table 1,
we found severely (≥90:10) skewed XCI in 30% (9/30) of
X-ALD carriers and in 8.6% (23/268) controls; moder-
ately (≥75:25) skewed XCI was found in 46.7% (14/30)
carriers and in 22.4% (60/268) controls; random XCI in
23.3% (7/30) carriers and in 69% (185/268) controls.
These findings indicate that the occurrence of both
severe and moderate XCI skewing is significantly higher
in X-ALD carriers vs. female controls (p = 0.0018 and p
= 0.0065; Fisher’s exact test - Table 1; Figure 1A). In con-
trast, we did not observe differences in XCI pattern
between symptomatic and asymptomatic carriers (p =
0.6472; Mann-Whitney test - Table 1; Figure 1B). Indeed,
we found severely skewed XCI in 3/9 symptomatic and
6/21 asymptomatic carriers (p = 1.00; Fisher’s exact test);
moderately skewed XCI in 3/9 symptomatic and 11/21
asymptomatic carriers (p = 0.4397; Fisher’s exact test);
random XCI in 3/9 symptomatic and 4/21 asymptomatic
carriers (p = 0.6402; Fisher’s exact test). The increase of
age has been associated, by other studies [16,17], with a
more frequent occurrence of preferential XCI but, in our
population, no correlation was found between the degree
of XCI of the X-ALD carriers and the age at evaluation
(p = 0.1550; Spearman r correlation). This suggests that
ABCD1 mutations may influence the XCI process, thus
making the possible correlation between older age and
preferential XCI irrelevant.
The overall results indicate that in X-ALD carriers the
skewed XCI in PBMCs is highly frequent and not
related to the manifestation of symptoms.
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Allele-specific expression of ABCD1 in X-ALD carriers
ABCD1 Allele-Specific Expression (ASE) was evaluated
in 25 X-ALD females carrying point mutations, as cases
showing deletions or mosaicisms were not suitable for
this experimental approach. As shown in Table 1, over-
all, we found a predominant expression (>60%) of one
allele with respect to the other in 23 out of the 25 car-
riers. Specifically, the mutant allele was more expressed
(range: 61% - 97%) than the wild-type in 19 out of 23
carriers and less expressed (range: 9% - 38%) in four out
of 23 carriers. Importantly, among the 23 carriers with a
predominant expression of one allele, we did not
observe any difference in ASE between the symptomatic
(n = 9) and the asymptomatic (n = 14) X-ALD carriers
(p = 0.0938; Mann-Whitney test). Indeed, the mutant
allele was predominantly expressed in 8 out of 9 symp-
tomatic X-ALD carriers, and in 11 out of 14 asympto-
matic carriers (p = 1.00; Fisher’s exact test). Therefore,
it is not surprising that 63 year-old patient F9 II:1 was
asymptomatic, despite the predominant (93%) expres-
sion of the mutant ABCD1 allele, while 73 year-old
patient F3 II:2 was symptomatic, despite the predomi-
nant (62%) expression of the wild-type ABCD1 allele.
We also found that the ABCD1 ASE pattern usually
mirrors the XCI pattern (i.e., their difference is <10%),
probably because one allele of ABCD1 is usually silenced
as result of the XCI. Representative results are shown in
Figure 2. Accordingly, we observed a significant correla-
tion between the ASE and XCI pattern (p < 0.0001,
Mann-Whitney test). Overall, our ASE data show that
the skewing of XCI toward the mutant ABCD1 allele is
common but not constant, and that the degree of
expression of the mutant ABCD1 allele is not related to
the presence of symptoms.
Biochemical characterization
In our series plasma concentration of C26:0, the ratio
C26:0 to C22:0, and the ratio C24:0 to C22:0 were all in
the normal range in about 15% of female carriers. Inter-
estingly, in 17 out of 22 assessable X-ALD carriers
(Table 1), we observed a significant positive correlation
between the degree of mutant ABCD1 expression and
the plasma concentration of C26:0 (p = 0.0201; Spear-
man r correlation) or the ratio C26:0 to C22:0 (p =
0.0141). This evidence demonstrates in vivo a previous
suggestion obtained by in vitro studies [18]. We note
that the remaining five out of 22 assessable carriers
were excluded from the statistical analysis, as the blood
for the VLCFA quantification was sampled a few years
before that for RNA extraction, and a different method
for their biochemical evaluation was used (Table 1).
Discussion
In this study we assessed the pattern of both X Chro-
mosome Inactivation (XCI) and ABCD1 allele-specific
expression (ASE) in the peripheral blood mononuclear
cells (PBMCs) of 30 female X-ALD carriers.
First, we observed, by a strictly controlled and very
reproducible experimental procedure, that the skewing
of XCI is significantly more common in X-ALD carriers
than in healthy females, in agreement with previous
findings [8].
Figure 1 Distribution of the X chromosome inactivation
pattern in peripheral blood mononuclear cells of X-ALD female
carriers and healthy controls. A) A severe (≥90:10) skewing of XCI
was found in 30% of X-ALD carriers (9/30) and 8.6% (23/268) of
healthy controls (HCs) (p = 0.0018, Fisher’s exact test); a moderate
(≥75:25) skewing of XCI was found in 46.7% of carriers (14/30) and
22.4% (60/268) of HCs (p = 0.0065, Fisher’s exact test); a random XCI
was found in 23.3% of carriers (7/30) and 69% (185/268) of HCs (p =
0.0001, Fisher’s exact test). B) A severe skewing of XCI was found in
3/9 symptomatic and 6/21 asymptomatic carriers (p = 1.00; Fisher’s
exact test); a moderate skewing of XCI was found in 3/9
symptomatic and 11/21 asymptomatic carriers (p = 0.4397; Fisher’s
exact test); a random XCI was found in 3/9 symptomatic and 4/21
asymptomatic carriers(p = 0.6402; Fisher’s exact test). Severe =
≥90:10; moderate = 75:25 to 89:11; random = 50:50 to 74:26.
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Second, by ASE analyses, we provided the first evi-
dence that, in X-ALD carriers, the active X chromosome
is typically the chromosome carrying the mutant ABCD1
allele.
It is already known that the severity of clinical symp-
toms in X-linked disorders can be influenced by XCI
skewing [19]. Our finding of a skewed XCI favoring the
inactivation of the wild-type allele is peculiar. Indeed,
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Figure 2 X Chromosome Inactivation (XCI) and ABCD1 Allele-Specific Expression (ASE) results in three representative samples. In the
left column the electropherograms of HUMARA alleles ND (upper) and D (lower) are depicted. For each sample, the peak lengths (bps) and the
corresponding area are indicated. The XCI results (ratio) are reported. In the right column the pyrograms of ASE experiments are shown and the
analysed sequences of cDNA, containing the mutations (the base-change is highlighted in bold), are indicated. The mutation site is boxed in
grey and the ASE (percentage of wt: mutant allele) is indicated. Sample F3 II-2shows a random XCI pattern and only a slight imbalance in ABCD1
ASE, suggesting that ABCD1 follows XCI; sample F5 II-1is characterized by severe skewing of both XCI and ABCD1 ASE, with an evident
preferential expression of the mutant allele; in F3 III-1 sample XCI is moderately skewed, as well as the ABCD1 ASE. ND = DNA not digested D =
DNA digested.
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the skewing of XCI seems to commonly favor the inacti-
vation of the mutant allele, thus explaining why, in
many severe X-linked disorders, female carriers may be
asymptomatic and have a severely skewed XCI [5,6].
This is the case of Lesch-Nyhan syndrome, in which the
cells expressing the wild-type allele of HPRT1 reproduce
faster, thus gradually causing decrease of the cells in
which the mutant allele is expressed [20]. Similarly, in
Wiskott-Aldrich syndrome, female carriers show prefer-
ential inactivation of the mutant allele in hematopoietic
cells [20]. In contrast, X-ALD had already been consid-
ered as the example of X-linked disease in which
ABCD1 mutations confer a proliferative advantage
rather than disadvantage, leading to XCI skewing in
favor of the X chromosome with the mutation
[5,6,8,18], an evidence here demonstrated in vivo. This
type of skewing could be due to a somatic selection in
favor of cells carrying an active mutated X chromosome,
after the X-inactivation process; in turn, this positive
selection might be due to a growth advantage of cells
expressing the defective ABCD1 allele [18]. However, it
remains enigmatic why cells expressing a mutant
ABCD1 should have a growth advantage over normal
cells. Reduced intracellular VLCFA b-oxidation, due to
the mutant ABCD1, and the consequent change of lipid
environment might be the basis for this phenomenon.
Moreover, we have investigated whether both the
skewing of XCI or the preferential expression of the
mutant ABCD1 allele were related to the neurological
manifestations affecting a subgroup of female carriers.
Our data do not support any significant correlation
between neurological manifestations of X-ALD carriers
and the XCI pattern or the degree of expression of the
mutant ABCD1 allele. The lack of correlation between
neurological manifestations and XCI pattern in PBMCs
is in agreement with previous data of Watkiss et al and
Jung et al [7,21], and in contrast with those of Maier et
al [8]. Since XCI pattern evaluation could be biased by
experimental procedures, it is conceivable that discre-
pancies between our results and previous results are due
to the different methodologies used. Indeed, our data
were obtained in a highly reproducible manner and in a
cohort of X-ALD female carriers larger than those pre-
viously studied. The lack of correlation between neuro-
logical manifestations and XCI pattern or degree of
expression of the mutant ABCD1 allele might be due to
the tissue analyzed, as the degree of XCI or mutant
ABCD1 expression might be different in the brain,
which is the tissue mainly involved in X-ALD. Although
XCI in brain from X-ALD carriers was not investigated,
a similar XCI pattern in blood and brain has been
observed [22]. To explore the maintenance of XCI pat-
tern in another tissue we performed XCI and ASE in
urinary sediment of a small subset of our patients (n =
8) and we have found that XCI and ASE pattern were
similar in the two cell types (data not shown).
Finally, our data reveal a significant and causative cor-
relation between the VCLFA plasma concentrations and
the degree of mutant ABCD1 allele-specific expression
in vivo. This is in agreement with previous in vitro
observations by Migeon et al [18].
In conclusion, we provide evidence that: i) in X-ALD
carriers the high frequency of non-random XCI usually
reflects the preferential expression of the mutant
ABCD1 allele, thus supporting by in vivo data the
hypothesis relating to the growth advantage of cells
expressing the mutant ABCD1 [18]; ii) the quantitative
allele-specific expression mirrors the plasma concentra-
tion of VCLFAs; iii) unfortunately, due to the lack of
correlation between XCI/ASE pattern and clinical symp-
toms, our results prove that these molecular values can-
not be considered in clinical practice as predictive
markers for the development of symptoms in X-ALD
carriers.
Additional material
Additional file 1: Pedigrees of 14 families in which X-ALD disease
segregates.
Additional file 2: HUMARA assay validation by Pyrosequencing. A -
The “HUMARA assay validation by Pyrosequencing” was designed to
verify the efficiency of the enzymatic digestions of samples. Hpa II and
Hha I restriction enzymes cut DNA at multiple sites of the Androgen
Receptor locus. Notably, they recognize and digest only the
unmethylated strand, whereas the methylated one remains undigested.
After enzymatic restriction, DNA was bisulphite converted, allowing the
conversion of the unmethylated “C” in “T” and PCR reaction was
performed on the converted DNA. Since the unmethylated DNA has
been cut by restriction enzymes, its amplification is virtually impossible.
Pyrosequencing analysis is able to detect the presence of PCR products
from the unmethylated strand (in which, after bisulphate conversion, all
“C” have switched to “T”), by the retrieval of residual “T” on the final
sequence. B - Example of representative pyrograms of the bisulphite-
converted DNA sample F10 III-3- PCR products: 1) undigested, 2)
showing incomplete or 3) complete digestion, using different
experimental conditions.
Additional file 3: PCR and pyrosequencing primer sequences,
together with the sequences analyzed by the PyroMarkID
instrument in ASE analyses.
Additional file 4: ABCD1 gene mutations in female carriers cohort.
The ABCD1 mutations are arranged based on the nucleotide position.
According to the X-linked Adrenoleukodsytrophy database (http://www.
x-ald.nl/), the amino acid substitution, the exon in which the mutation
occurs, and the protein status in fibroblasts are indicated. Note that two
new mutations (c.652C > T and c.664G > T) were found to be in cis on
the same allele. ALDP = AdrenoLeukoDystrophy Protein; N/A = not
applicable; n.d. = no data provided; * = new mutation.
Acknowledgements
This work was partially supported by grants from FP7-HEALTH - LeukoTreat
no. 241622, and from Associazione Italiana Studio Malformazioni Onlus. We
thank the patients and their relatives who made their blood, DNA and RNA
available for analyses, and Nutricia Italia for kindly providing the reagents
needed for Pyrosequencing™ analyses.
Salsano et al. Orphanet Journal of Rare Diseases 2012, 7:10
http://www.ojrd.com/content/7/1/10
Page 8 of 9
Author details
1Department of Clinical Neurosciences, Fondazione IRCCS, Istituto
Neurologico “C. Besta”, Milan, Italy. 2Department of Medicine, Surgery and
Dentistry, Università degli Studi di Milano, Milan, Italy. 3Pathology Unit,
Fondazione IRCCS, Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy.
4Department of Diagnostics and Applied Technology, Fondazione IRCCS,
Istituto Neurologico “C. Besta”, Milan, Italy. 5Department of Pediatric
Neurosciences, Fondazione IRCCS, Istituto Neurologico “C. Besta”, Milan, Italy.
Authors’ contributions
ES and ST are the principal investigators of the study: they planned the
experimental tasks and the statistical analysis plan; ES also recruited the
subjects for the study. SMS designed and implemented data collection and
revised the draft paper; PC designed and implemented the experiments; BC
analyzed and monitored the data; CG monitored data collection and
performed statistical analyses; MR implemented the data and contributed to
statistical analysis; VP collected and analyzed the data; CM recruited the
subjects and revised data analyses; DP participated to experimental plan and
drafted and revised the paper; MM coordinated the experimental plan and
analyzed the data. She critically revised the manuscript and the final
approval of the version to be published. GU initiated the collaborative
project, recruited the subjects for the study, obtained funding for the study,
drafted and revised the paper for intellectual content; she is guarantor. All
authors read and approved the final manuscript.
Received: 6 October 2011 Accepted: 26 January 2012
Published: 26 January 2012
References
1. Fourcade S, López-Erauskin J, Galino J, Duval C, Naudi A, Jove M, Kemp S,
Villarroya F, Ferrer I, Pamplona R, Portero-Otin M, Pujol A: Early oxidative
damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum
Mol Genet 2008, 17:1762-1773.
2. Moser HW, Loes DJ, Melhem ER, Raymond GV, Bezman L, Cox CS, Lu SE: X-
Linked adrenoleukodystrophy: overview and prognosis as a function of
age and brain magnetic resonance imaging abnormality. A study
involving 372 patients. Neuropediatrics 2000, 31:227-239.
3. Schmidt S, Träber F, Block W, Keller E, Pohl C, von Oertzen J, Schild H,
Schlegel U, Klockgether T: Phenotype assignment in symptomatic female
carriers of X-linked adrenoleukodystrophy. J Neurol 2001, 248:36-44.
4. Dobyns WB, Filauro A, Tomson BN, Chan AS, Ho AW, Ting NT,
Oosterwijk JC, Ober C: Inheritance of most X-linked traits is not dominant
or recessive, just X-linked. Am J Med Genet A 2004, 129A:136-143.
5. Van den Veyver IB: Skewed X inactivation in X-linked disorders. Semin
Reprod Med 2001, 19:183-191.
6. Ørstavik KH: X chromosome inactivation in clinical practice. Hum Genet
2009, 126:363-373.
7. Watkiss E, Webb T, Bundey S: Is skewed X inactivation responsible for
symptoms in female carriers for adrenoleucodystrophy? J Med Genet
1993, 30:651-654.
8. Maier EM, Kammerer S, Muntau AC, Wichers M, Braun A, Roscher AA:
Symptoms in carriers of adrenoleukodystrophy relate to skewed X
inactivation. Ann Neurol 2002, 52:683-688.
9. Semmler A, Köhler W, Jung HH, Weller M, Linnebank M: Therapy of X-
linked adrenoleukodystrophy. Expert Rev Neurother 2008, 8:1367-1379.
10. Uziel G, Bertini E, Bardelli P, Rimoldi M, Gambetti M: Experience on therapy
of adrenoleukodystrophy and adrenomyeloneuropathy. Dev Neurosci
1991, 13:274-279.
11. Johnson DW: Alkyldimethylaminoethyl ester iodides for improved
analysis of fatty acids by electrospray ionization tandem mass
spectrometry. Rapid Commun Mass Spectrom 2000, 14:2019-2024.
12. Johnson DW: A rapid screening procedure for the diagnosis of
peroxisomal disorders: quantification of very long-chain fatty acids, as
dimethylaminoethyl esters, in plasma and blood spots, by electrospray
tandem mass spectrometry. J Inherit Metab Dis 2000, 23:475-486.
13. Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW: Methylation
of HpaII and HhaI sites near the polymorphic CAG repeat in the human
androgen-receptor gene correlates with X chromosome inactivation. Am
J Hum Genet 1992, 51:1229-1239.
14. Beever C, Lai BP, Baldry SE, Peñaherrera MS, Jiang R, Robinson WP,
Brown CJ: Methylation of ZNF261 as an assay for determining X
chromosome inactivation patterns. Am J Med Genet 2003, 120A:439-441.
15. Miozzo M, Selmi C, Gentilin B, Grati FR, Sirchia S, Oertelt S, Zuin M,
Gershwin ME, Podda M, Invernizzi P: Preferential X chromosome loss but
random inactivation characterize primary biliary cirrhosis. Hepatology
2007, 46:456-462.
16. Hatakeyama C, Anderson CL, Beever CL, Peñaherrera MS, Brown CJ,
Robinson WP: The dynamics of X-inactivation skewing as women age.
Clin Genet 2004, 66:327-332.
17. Busque L, Paquette Y, Provost S, Roy DC, Levine RL, Mollica L, Gilliland DG:
Skewing of X-inactivation ratios in blood cells of aging women is
confirmed by independent methodologies. Blood 2009, 113:3472-3474.
18. Migeon BR, Moser HW, Moser AB, Axelman J, Sillence D, Norum RA:
Adrenoleukodystrophy: evidence for X linkage, inactivation, and
selection favoring the mutant allele in heterozygous cells. Proc Natl Acad
Sci USA 1981, 78:5066-5070.
19. Migeon BR: Non-random X chromosome inactivation in mammalian cells.
Cytogenet Cell Genet 1998, 80:142-148.
20. Migeon BR: The role of X inactivation and cellular mosaicism in women’s
health and sex-specific diseases. JAMA 2006, 295:1428-1433.
21. Jung HH, Wimplinger I, Jung S, Landau K, Gal A, Heppner FL: Phenotypes
of female adrenoleukodystrophy. Neurology 2007, 68:960-961.
22. Bittel DC, Theodoro MF, Kibiryeva N, Fischer W, Talebizadeh Z, Butler MG:
Comparison of X-chromosome inactivation patterns in multiple tissues
from human females. J Med Genet 2008, 45:309-313.
23. Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, Mills JA,
Weiner HL: Intensive immunosuppression in progressive multiple
sclerosis. A randomized, three-arm study of high-dose intravenous
cyclophosphamide, plasmaexchange, and ACTH. N Engl J Med 1983,
308:173-180.
24. van Geel BM, Koelman JH, Barth PG, Ongerboer de Visser BW: Peripheral
nerve abnormalities in adrenomyeloneuropathy: A clinical and
electrodiagnostic study. Neurology 1996, 46:112-118.
doi:10.1186/1750-1172-7-10
Cite this article as: Salsano et al.: Preferential expression of mutant
ABCD1 allele is common in adrenoleukodystrophy female carriers but
unrelated to clinical symptoms. Orphanet Journal of Rare Diseases 2012
7:10.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Salsano et al. Orphanet Journal of Rare Diseases 2012, 7:10
http://www.ojrd.com/content/7/1/10
Page 9 of 9
